SUMMARY Previous studies of phenytoin neuropathy in selected groups of chronic epileptic patients on polytherapy have indicated a widely varying incidence of clinical or electrophysiological abnormalities. In 51 previously untreated epileptic patients followed prospectively on phenytoin or carbamazepine monotherapy, assisted by blood level monitoring, for 1-5 years we found no clinical evidence of neuropathy. Eighteen per cent of the phenytoin group and none of the carbamazepine group had mild electrophysiological changes (abnormalities of sensory action potentials or sensory conduction). In the former group the occurrence of the electrophysiological abnormalities was possibly related to previous exposure to high phenytoin or low folate levels or both. In 10 chronic epileptic patients we demonstrated reversible slowing of sensory nerve conduction during phenytoin intoxication. In six selected epileptic patients on chronic barbiturate monotherapy we found clinical evidence of neuropathy in two and electrophysiological abnormalities in five, including reversible slowing of sensory conduction during intoxication in one. This suggests that barbiturate drugs may, like phenytoin, also contribute to anticonvulsant neuropathy. Careful monitoring of single drug therapy with avoidance of acute toxicity may reduce the risk of chronic anticonvulsant neuropathy.
Isolated cases of peripheral neuropathy associated with phenytoin therapy in epileptic patients have been reported over many years.1-5 However, only in the last 15 years has the subject been investigated in detail. Since In order to control for these problems we undertook the following investigations: (1) an electrophysiological study of sensory nerve function during and after exposure to high serum levels of phenytoin, (2) a clinical and electrophysiological study of previously untreated epileptic patients who had been carefully monitored prospectively on phenytoin or carbamazepine monotherapy for 1-5 years, (3) a clinical and electrophysiological study of chronic. epileptic patients on barbiturate monotherapy.
Patients (table 2) Group A Twenty healthy subjects (age 22-69 yr), who had never taken anticonvulsant drugs, constituted the control group.
Group B Ten chronic epileptic patients taking phenytoin were examined on two occasions (a) with a serum phenytoin level higher than 120 ,umol/l, and (b) after reduction of the phenytoin level below 80 ,umol/l.
Group C Thirty-two previously untreated epileptic patients (age 15-68 yr) who had been taking phenytoin alone continuously for 2-5 years, and whose blood level at the time of testing was less than 120 ,umol/l.
Group D Nineteen previously untreated epileptic patients (age 10-59 yr) who had been taking carbamazepine alone continuously over a period of 1-3 years.
In groups C and D the patients had been regularly supervised by the authors since the commencement of anticonvulsant therapy. Serum In every subject the sensory action potentials and conduction velocities of the median and sural nerves were measured according to the method of Burke et al. 2 Standard electrophysiological techniques for stimulation and recording were employed using surface electrodes and averaging 32 supramaximal evoked potentials using a Medelec MS6 electromyograph. In all cases the proximal sural potentials were obtained from both lower limbs, and median nerve potentials from the index and third fingers of both hands, and the best measurements used. The conduction velocity of the fastest conducting fibres were obtained by dividing the distance from the cathode to the nearest recording electrode by the latency to onset of the first negative deflection. The amplitude of the averaged response was measured peak to peak. The limbs were warmed and the skin temperature was kept at 32°C or more in all cases. Scrupulous attention was paid to careful technique as emphasised by Buchthal In table 6 , the 26 patients with normal and the six with abnormal electrophysiological findings are compared. At the time of testing no differences were found in the serum phenytoin, serum or red cell folate levels although there were trends towards higher phenytoin and lower folate levels in the electrophysiologically abnormal group. However, the number of patients in the two subgroups with previous exposure to high phenytoin levels, or to low folate levels were different. Sixty-seven per cent of those with abnormal and 14% of those with normal electrophysiological findings had been previously exposed to high serum phenytoin levels (p = <0-01 X2 Yates correction); 83% of those with abnormal and 17% of those with normal electrophysiological findings had been exposed to subnormal folate levels (p = <0-001 X2 Yates correction). There was no relationship of age, sex or duration of treatment to the electrophysiological findings.
Group D (carbamazepine monotherapy) (table 7) There were no clinical or electrophysiological abnormalities in any of the 19 patients examined. A moderately high carbamazepine blood level (be- group.bmj.com on June 21, 2017 -Published by http://jnnp.bmj.com/ Downloaded from tween 42-52 gmol/1) had been recorded in four patients (three at the time of testing) and a low serum folate in one patient during their follow up but in none'of these were there any electrophysiological abnormalities. There was no relationship of age, sex, duration of treatment, serum carbamazepine, serum or red cell folate levels to any of the electrophysiological data.
Group E (barbiturate monotherapy) (table 8) In two cases there were clinical abnormalities (absent ankle jerks in both and impaired vibration sense in the feet in one). In one patient, case 6, the sural nerve action potential was absent while the patient was clinically intoxicated (phenobarbitone level 228 ,umol/l) and had returned to normal six weeks later when the signs of intoxication had regressed (phenobarbitone level 95 ,umol/l). Of the other five cases, the sural conduction was abnormal in four (abnormal sensory action potential in two and abnormal conduction velocity in two), and median nerve conduction was abnormal in three (subnormal sensory action potential).
Discussion
We have shown that exposure to high phenytoin levels causes a reversible slowing of sensory nerve conduction velocity (table 4, fig) . Similar changes have been previously reported in animal experiments5157 in vitro experiments1416 and in motor conduction in human subjects.'8 1I The slowing was greatest in the lower limbs. Fifteen per cent or more reduction of velocity was noted in the sural nerve in eight of the 10 cases and in the median nerve in six of the 10 cases. The mean sural nerve conduction velocity was 22% lower and the mean median nerve conduction velocity 11% lower during intoxication. This is comparable to the mean 13% reduction noted by Birket-Smith and Krogh19 in motor conduction during exposure to high phenytoin levels. A single patient was examined during and after exposure to high barbiturate levels and a similar reversible effect was noted on sural (but not median) conduction, suggesting that the effect is not confined to phenytoin alone. Several patients on carbamazepine monotherapy were examined with moderately high levels but no effect on peripheral nerve function was found.
Previous reports of phenytoin neuropathy have suggested that the incidence of clinical neuropathy varies between 0-33% and of electrophysiological neuropathy between 0-89% (table 1). The possible reasons for these discordant conclusions have already been referred to and include (1) the failure to recognise the reversible slowing of conduction associated with toxic phenytoin levels (2) the study of selected groups of chronic patients on polytherapy without allowing for the possible contribution of other drugs, and (3) failure to study other factors associated with prolonged therapy. In order to control for these problems as far as possible, we studied epileptic patients (1) who had been newly diagnosed and who had subsequently taken phenytoin or carbamazepine continuously for between 1-5 years, (2) who had no other anticonvulsant drugs, (3) whose serum drug levels and folate status had been prospectively monitored throughout this period, (4) who were not intoxicated at the time of testing, and (5) who had been carefully screened to exclude other potential causes of neuropathy. We were unable to study patients on barbiturate therapy from the onset of treatment, but we were able to include a small group of selected chronic patients who had been on barbiturate monotherapy for many years.
Among the patients we followed prospectively on monotherapy (groups C and D) we found no clinical or electrical abnormalities associated with carbamazepine. However, in the patients on phenytoin, although there were no clinical signs of neuropathy, 18% had slight electrophysiological abnormalities. Although the small group of patients on barbiturate monotherapy are not strictly comparable because they were selected chronic patients who had not been followed prospectively, nevertheless, it is of considerable interest that two of them had clinical signs of neuropathy and all but one had electrophysiological abnormalities. Further one patient who was reexamined after reduction of a toxic phenobarbitone level also showed improvement in sensory conduction. These observations suggest that phenobarbitone and primidone may, like phenytoin, cause both reversible and more permanent peripheral nerve dysfunction, and cast doubt on many of the reports of phenytoin neuropathy in which barbiturates were a frequent co-medication (table 1) .
Among patients on phenytoin monotherapy some interesting differences emerged when the six patients with electrophysiological abnormalities were compared with the remaining 26 without such changes (table 5). The abnormal subgroup had significantly more past evidence of exposure to toxic levels of the drug and to low folate levels. This suggests the possibility that permanent neuropathy due to this drug (and perhaps barbiturates) may result from prolonged or repeated episodes of intoxication or folate deficiency. This would be consistent with the studies reporting a high incidence of clinical neuropathy in chronic epileptic patients who had a frequent history of past toxicity or high drug levels at the time of testing.9 12 There is evidence that severe folate deficiency in non-epileptic subjects may lead to peripheral neuropathy, amongst other neuro-psychiatric complications,24 25 and the relationship of the generally milder prolonged anticonvulsant induced folate deficiency to neuropathy in epileptic patients is discussed elsewhere.22 " The pathophysiological basis of anticonvulsant neuropathy is obscure. The predominant electrophysiological change amongst the patients taking phenytoin at therapeutic levels was a reduction in the amplitude of the sensory action potential with relative preservation of the conduction velocity, and this contrasts with the moderate slowing of conduction noted amongst those intoxicated with phenytoin. This suggests that the two effects on the peripheral nerve are distinct, although repeated episodes of the latter may ultimately lead to the former.
Finally although the duration of follow-up of our patients on phenytoin or carbamazepine is relatively short (1-5 years) our observations to date suggest that anticonvulsant neuropathy, as with other chronic complications of antiepileptic therapy, could be greatly reduced by careful monitoring of single drug treatment and the avoidance as far as possible of acute toxicity or polytherapy.'0
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